Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 3, 2001, Pages 705-715

  Glaser, Christoph M ^a   Millesi, Werner ^a   Kornek, Gabriela V ^a   Lang, Susanna ^a   Schüll, Birgit ^a   Watzinger, Franz ^a   Selzer, Edgar ^b   Lavey, Robert S ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chemotherapy; Erythropoietin; Hemoglobin; Oral cavity cancer; Radiation therapy

Indexed keywords

CELLS; CHEMOTHERAPY; HEMOGLOBIN; PATIENT TREATMENT; RADIOTHERAPY; SURGERY; TUMORS;

LOCOREGIONAL TUMOR CONTROL;

ONCOLOGY;

FLUOROURACIL; MITOMYCIN C; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH CAVITY; MULTIVARIATE ANALYSIS; OROPHARYNX; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FLUOROURACIL; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; MOUTH NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES;

EID: 0035400246     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01488-2     Document Type: Article

References (54)

1. Preoperative simultaneous chemoradiotherapy in locally advanced cancer of the oral cavity and oropharynx
2. Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity; An analysis of long-term results
3. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx
4. Does initial hemoglobin level modify the efficacy of radiosensitizers? An analysis of the MRC misonidazole studies in head and neck cancer and cervix cancer
5. T1/T2 glottic cancer managed by external beam radiotherapy; The influence of pretreatment hemoglobin on local control
6. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx
7. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma
8. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma; A secondary analysis of RTOG 85-27
9. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx; Report from the DAHANCA 2 Study
10. A randomized double blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
11. Clinical radiobiology of squamous cell carcinoma of the oropharynx
12. A multivariate study of the prognosis of oral squamous cell carcinomas
13. Primary radiotherapy of larynx and pharynx carcinoma-an analysis of some factors influencing local control and survival
14. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer; A prospective study
15. Significance of hemoglobin concentration for treatment outcome
16. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients
17. Recombinant human erythropoietin in patients with ovarian carcinoma and anemia secondary to cisplatin and carboplatin chemotherapy; Preliminary results
18. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
19. Recombinant human erythropoietin treatment in cisplatin-associated anemia; A randomized, double-blind trial with placebo
20. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer
21. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
22. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type; Results from a prospective community oncology study
23. Erythropoietin reduces anemia and transfusions
24. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lympoma; Dose finding and identification of predictors of response
25. Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia
26. Erythropoietin (EPO) prevents anemia during concurrent chemo-radiation therapy (RT) for locally-advanced inoperable non-small cell lung cancer (NSCLC)
27. Erythropoietin increases hemoglobin in cancer patients during radiation therapy
28. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy; Final report of a randomized, open-labeled, phase II trial
29. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
30. Erythropoietin for patients undergoing radiotherapy; A pilot study
31. Nonparametric estimation from incomplete observations
32. Evaluation of survival data and two new rank order statistics arising in its consideration
33. Impact of the extent of parametrical involvement in patients with carcinoma of the uterine cervix
34. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix
35. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
36. The influence of haemoglobin concentration on the response to radiotherapy
37. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy; Results of a retrospective study of 386 patients
38. The significance of anemia in clinical radiation therapy
39. Reduced oxygen enhancement ratio at low doses of ionizing radiation
40. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
41. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
42. Hypoxia and radiation response in human tumors
43. Oxygenation predicts radiation response and survival in patients with cervix cancer
44. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide
45. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents
46. 2 during early radiotherapy in cervical cancers; Improved local control in primarily hypoxic tumors with 'reoxygenation' and the impact of hemoglobin
47. Human erythropoietin induces a proangiogenic phenotypye in cultured endothelial cells and stimulates neovascularization in vivo
48. Blood transfusion and other risk factors for recurrence of cancer of the head and neck
49. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?
50. Prognostic significance of vascular endothelial growth factor protein levels in oral, and oropharyngeal carcinoma